Gapping down
In reaction to disappointing earnings/guidance:
- THO -4.1%
M&A news:
- DPLO -31.7% (to be acquired by UnitedHealth's (UNH) OptumRx for $4.00/share in cash)
Other news:
- KALV -17.7% (announced results of the Phase 2 clinical trial evaluating the use of KVD001 )
- MNRL -4.4% (commences 11 mln common stock offering; 6 mln by the co and 5 mln by the selling stockholders)
- SYNH -3% (approves expansion and extension of the Company's existing stock repurchase program)
- AUPH -2.8% (commences registered underwritten public offering of $150 mln of its common shares)
- ERIC -0.7% (reaches resolution on US FCPA Investigations; combined payment of $1.06 bln)
- LITE -0.5% (to offer $850 mln aggregate principal amount of convertible senior notes due in 2026)
Analyst comments:
- M -2.1% (downgraded to Sell at Goldman)
- MMM -1.3% (downgraded to Neutral at Citigroup)
- ORLY -1.3% (downgraded to Neutral from Buy at Goldman)
